medalphabetМедицинский алфавитMedical alphabet2078-56312949-2807ООО «Альфмед»10.33667/2078-5631-2021-34-8-11medalphabet-2337Research ArticleДЕРМАТОЛОГИЯDERMATOLOGYАнтибиотики в профилактике кожных токсических реакций ингибиторов рецептора эпидермального фактора роста (обзор литературы)Antibiotics in prevention of skin toxic reactions of epidermal growth factor receptor inhibitors (literature review)https://orcid.org/0000-0002-5044-5265КругловаЛ. С.KruglovaL. S.

Круглова Лариса Сергеевна, д. м. н., проректор по учебной работе, зав. кафедрой дерматовенерологии и косметологии

Москва

Kruglova Larisa S., DM Sci (habil.), vice-rector for academic affairs, head of Dept of Dermatovenereology and Cosmetology

Moscow

kruglovals@mail.ruКоролеваИ. А.KorolevaI. A.

Королева Ирина Альбертовна, д. м. н., проф. кафедры клинической медицины последипломного образования

Самара

Koroleva Irina A., DM Sci (habil.), professor at Dept of Clinical Medicine of Postgraduate Education

Samara

ФГБУ ДПО «Центральная государственная медицинская академия» Управления делами Президента РоссииРоссияCentral State Medical Academy of the Administrative Department of the President of RussiaRussian FederationКафедра клинической медицины последипломного образования ЧУ ООВО «Медицинский университет „РЕАВИЗ“»Russian Federation202117122021034Дерматология (3)811Copyright © Круглова Л.С., Королева И.А., 20212021Круглова Л.С., Королева И.А.Kruglova L.S., Koroleva I.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.med-alphabet.com/jour/article/view/2337

Статья носит обзорный характер и содержит актуальную информацию по применению антибиотиков тетрациклинового ряда в профилактике акнеподобной сыпи у пациентов, получающих терапию ингибиторами рецептора эпидермального фактора роста. По данным исследований, профилактика кожной токсичности необходима для сохранения эффективности противоопухолевого эффекта ингибиторов EGFR и минимизации негативного влияния нежелательных явлений со стороны кожных покровов на качество жизни пациентов. Использование антибиотиков тетрациклинового ряда в комплексе с топической терапией и фотозащитой для профилактики акненоподобной сыпи на фоне применения ингибиторов EGFR является весьма безопасным методом при длительном применении. Из антибактериальных препаратов для профилактики акнеподобной сыпи наиболее целесообразно назначение доксициклина в дозе 100 мг в сутки с первого дня приема ингибиторов EGFR.

The article is an overview and contains up-to-date information on the use of tetracycline antibiotics in the prevention of acne-like rash in patients receiving therapy with epidermal growth factor receptor inhibitors. According to studies, prevention of skin toxicity is necessary to maintain the effectiveness of the antitumor effect of EGFR inhibitors and to minimize the negative effect of adverse effects from the skin on the quality of life of patients. The use of tetracycline antibiotics in combination with topical therapy and photoprotection for the prevention of acne-like rash against the background of the use of EGFR inhibitors is a fairly safe method for long-term use. Of the antibacterial drugs for the prevention of acne-like rash, the most advisable is the appointment of doxycycline at a dose of 100 mg per day from the first day of taking EGFR inhibitors.

злокачественные новообразованияингибиторы рецептора эпидермального фактора ростакожные токсические реакцииакнеподобная сыпьпрофилактикаантибиотики тетрациклинового рядаmalignant neoplasmsepidermal growth factor receptor inhibitorsskin toxic reactionsacne-like rashprophylaxistetracycline antibioticsReferencesОтчет ВОЗ за 2018 г.WHO Report, 2018.Каприн А.Д., Старинский В. В., Петрова Г. В. Злокачественные новообразования в России в 2018 году (заболеваемость и смертность). ФГБУ «МНИОИ им. П. А. Герцена». М., 2019. 250 с. Kaprin A. D., Starinskiy V. V., Petrova G. V. Malignant neoplasms in Russia in 2018 (morbidity and mortality). MNIOI n. a. P. A. Herzen. M., 2019. 250 p.Kaprin A. D., Starinskiy V. V., Petrova G. V. Malignant neoplasms in Russia in 2018 (morbidity and mortality). MNIOI n. a. P. A. Herzen. M., 2019. 250 p.Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020 Jan; 70 (1): 7–30.Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020 Jan; 70 (1): 7–30.Переводчикова Н. И. Таргетные препараты и их место в современной терапии опухолевых заболеваний. Клиническая онкогематология. Фундаментальные исследования и клиническая практика. 2009. 2 (4), 367–373. Translator N. I. Targeted drugs and their place in modern therapy of tumor diseases. Clinical hematology oncology. Basic research and clinical practice. 2009. 2 (4), 367–373.Translator N. I. Targeted drugs and their place in modern therapy of tumor diseases. Clinical hematology oncology. Basic research and clinical practice. 2009. 2 (4), 367–373.Lynch TJ, Kim ES, Eaby B, et al. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: An evolving paradigm in clinical management. Oncologist 2007; 12: 610–621.Lynch TJ, Kim ES, Eaby B, et al. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: An evolving paradigm in clinical management. Oncologist 2007; 12: 610–621.Keefe DM, Bateman EH. Tumor control versus adverse events with targeted anticancer therapies. Nat Rev Clin Oncol.2012. 9: 98–109.Keefe DM, Bateman EH. Tumor control versus adverse events with targeted anticancer therapies. Nat Rev Clin Oncol.2012. 9: 98–109.Chan A, Chiang YY, Low XH, et al. Affordability of cancer treatment for aging cancer patients in Singapore: an analysis of health, lifestyle, and financial burden. Support Care Cancer. 2013. 21: 3509–3517.Chan A, Chiang YY, Low XH, et al. Affordability of cancer treatment for aging cancer patients in Singapore: an analysis of health, lifestyle, and financial burden. Support Care Cancer. 2013. 21: 3509–3517.Liu HB, Wu Y, Lv TF et al. Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis. PLoS One. 2013. 8: e55128.Liu HB, Wu Y, Lv TF et al. Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis. PLoS One. 2013. 8: e55128.Lacouture ME, Anadkat MJ, Bensadoun RJ et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer.2011. 19: 1079–1095.Lacouture ME, Anadkat MJ, Bensadoun RJ et al. Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer.2011. 19: 1079–1095.Hofheinz RD, Segaert S, Safont MJ, Demonty G, Prenen H. Management of adverse events during treatment of gastrointestinal cancers with epidermal growth factor inhibitors. Crit Rev Oncol Hematol. 2017. 114: 102–113.Hofheinz RD, Segaert S, Safont MJ, Demonty G, Prenen H. Management of adverse events during treatment of gastrointestinal cancers with epidermal growth factor inhibitors. Crit Rev Oncol Hematol. 2017. 114: 102–113.Королева И. А., Болотина Л. В., Гладков О. А., Горбунова В. А., Круглова Л. С., Манзюк Л. В. и соавт. Практические рекомендации по лекарственному лечению дерматологических реакций у пациентов, получающих противоопухолевую лекарственную терапию. Злокачественные опухоли: практические рекомендации RUSSCO, 2020 (том 10). 42. Koroleva I. A., Bolotina L. V., Gladkov O. A., Gorbunova V. A., Kruglova L. S., Manzyuk L. V. et al. Practical recommendations for drug treatment of dermatological reactions in patients receiving anticancer drug therapy. Malignant tumors: practical guidelines RUSSCO, 2020 (volume 10).Koroleva I. A., Bolotina L. V., Gladkov O. A., Gorbunova V. A., Kruglova L. S., Manzyuk L. V. et al. Practical recommendations for drug treatment of dermatological reactions in patients receiving anticancer drug therapy. Malignant tumors: practical guidelines RUSSCO, 2020 (volume 10).Lynch TJ, Kim ES, Eaby B, et al. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: An evolving paradigm in clinical management. Oncologist. 2007. 12: 610–621.Lynch TJ, Kim ES, Eaby B, et al. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: An evolving paradigm in clinical management. Oncologist. 2007. 12: 610–621.Guillot B, Bessis D. Aspects cliniques et prise en charge des effets secondaires cutanés des inhibiteurs du récepteur à l’EGF. Ann Dermatol Venereol. 2006. 133: 1017–1020.Guillot B, Bessis D. Aspects cliniques et prise en charge des effets secondaires cutanés des inhibiteurs du récepteur à l’EGF. Ann Dermatol Venereol. 2006. 133: 1017–1020.Peréz-Soler R, Saltz L. Cutaneous adverse effects with HER 1/EGFR-targeted agents: Is there a silver lining? J Clin Oncol. 2005. 23: 5235–5246.Peréz-Soler R, Saltz L. Cutaneous adverse effects with HER 1/EGFR-targeted agents: Is there a silver lining? J Clin Oncol. 2005. 23: 5235–5246.Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16: 1425–1433.Segaert S, Van Cutsem E. Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors. Ann Oncol 2005; 16: 1425–1433.Wagner LI, Lacouture ME. Dermatologic toxicities associated with EGFR inhibitors: The clinical psychologist’s perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology (Williston Park) 2007; 21: 34–36.Wagner LI, Lacouture ME. Dermatologic toxicities associated with EGFR inhibitors: The clinical psychologist’s perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology (Williston Park) 2007; 21: 34–36.Bouché O, Scaglia E, Reguiai Z, Singha V, Brixi-Benmansour H, Lagarde S. Targeted biotherapies in digestive oncology: Management of adverse effects. Gastroenterol Clin Biol. 2009. 33: 306–322.Bouché O, Scaglia E, Reguiai Z, Singha V, Brixi-Benmansour H, Lagarde S. Targeted biotherapies in digestive oncology: Management of adverse effects. Gastroenterol Clin Biol. 2009. 33: 306–322.Kafatos G, Dube S, Burdon P, et al. Management of EGFR Inhibitor-induced Skin Toxicity and Factors Impacting Patients’ Adherence to Skin Toxicity Treatment: Health Care Provider and Patient Surveys in European Oncology Centers. Clin Colorectal Cancer. 2020 Jun; 19 (2): 100–108. e9.Kafatos G, Dube S, Burdon P, et al. Management of EGFR Inhibitor-induced Skin Toxicity and Factors Impacting Patients’ Adherence to Skin Toxicity Treatment: Health Care Provider and Patient Surveys in European Oncology Centers. Clin Colorectal Cancer. 2020 Jun; 19 (2): 100–108. e9.Petrelli F, Borgonovo K., Cabiddu M., et al. Antibiotic prophylaxis for skin toxicity induced by antiepidermal growth factor receptor agents: a systematic review and meta-analysisBritish Journal of Dermatology (2016) 175, pp. 1166–1174.Petrelli F, Borgonovo K., Cabiddu M., et al. Antibiotic prophylaxis for skin toxicity induced by antiepidermal growth factor receptor agents: a systematic review and meta-analysisBritish Journal of Dermatology (2016) 175, pp. 1166–1174.Deplanque G, et al. J Am Acad Dermatol 2016; 74: 1077–85.Deplanque G, et al. J Am Acad Dermatol 2016; 74: 1077–85.Lacouture ME. et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer J Clin Oncol. 2010. 28 (8). 1351–7.Lacouture ME. et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer J Clin Oncol. 2010. 28 (8). 1351–7.Ramirez Daffos P, Jiménez E, Bolaños Naranjo M, et al. Doxycycline as preventive treatment of skin toxicity in patients with metastatic colorectal cancer treated with an anti-EGFR and chemotherapy. Annals of oncology. 20221. EudraCT: 2017–004413–98 NCT03448731.Ramirez Daffos P, Jiménez E, Bolaños Naranjo M, et al. Doxycycline as preventive treatment of skin toxicity in patients with metastatic colorectal cancer treated with an anti-EGFR and chemotherapy. Annals of oncology. 20221. EudraCT: 2017–004413–98 NCT03448731.Deplanque G, Gervais R, Vergnenegre A, et al. CYTAR investigators. Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial. J Am Acad Dermatol. 2016 Jun; 74 (6): 1077–85.Deplanque G, Gervais R, Vergnenegre A, et al. CYTAR investigators. Doxycycline for prevention of erlotinib-induced rash in patients with non-small-cell lung cancer (NSCLC) after failure of first-line chemotherapy: A randomized, open-label trial. J Am Acad Dermatol. 2016 Jun; 74 (6): 1077–85.Ramirez P., Jimenez P., Oronco J. P., et al. Doxycycline as preventive treatment of skin toxicity in patients with metastatic colorectal cancer treated with an anti-EGFR and chemotherapy. World Gastrointestinal Cancer Congress. 2021. Poster ID: 173.Ramirez P., Jimenez P., Oronco J. P., et al. Doxycycline as preventive treatment of skin toxicity in patients with metastatic colorectal cancer treated with an anti-EGFR and chemotherapy. World Gastrointestinal Cancer Congress. 2021. Poster ID: 173.Lacouture ME, Mitchell EP, Piperdi B, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010 Mar 10; 28 (8): 1351–7.Lacouture ME, Mitchell EP, Piperdi B, et al. Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive Skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol. 2010 Mar 10; 28 (8): 1351–7.Jatoi A, Rowland K, Sloan JA, et al. Tetracycline to pre-vent epidermal growth factor receptor inhibitor–induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N 03CB). Cancer 2008; 113: 847–53.Jatoi A, Rowland K, Sloan JA, et al. Tetracycline to pre-vent epidermal growth factor receptor inhibitor–induced skin rashes: results of a placebo-controlled trial from the North Central Cancer Treatment Group (N 03CB). Cancer 2008; 113: 847–53.Scope A, et al. J Clin Oncol 2007; 25: 5390–6.Scope A, et al. J Clin Oncol 2007; 25: 5390–6.Kobayashi Y, et al. Future Oncol 2015; 11: 617–27.Kobayashi Y, et al. Future Oncol 2015; 11: 617–27.Nakata Komori K, Takamichi S. Pre-emptive oral clarithromycin reduces the skin toxicity of panitumumab treatment for metastatic colorectal cancer. International Journal of Colorectal Disease. 2021. 10.1007/s00384–021–04002–9.Nakata Komori K, Takamichi S. Pre-emptive oral clarithromycin reduces the skin toxicity of panitumumab treatment for metastatic colorectal cancer. International Journal of Colorectal Disease. 2021. 10.1007/s00384–021–04002–9.

The authors declare that there are no conflicts of interest present.